These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 8159859)
21. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Gent M; Blakely JA; Easton JD; Ellis DJ; Hachinski VC; Harbison JW; Panak E; Roberts RS; Sicurella J; Turpie AG Stroke; 1988 Oct; 19(10):1203-10. PubMed ID: 3051529 [TBL] [Abstract][Full Text] [Related]
22. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Haynes RB; Sandler RS; Larson EB; Pater JL; Yatsu FM Arch Intern Med; 1992 Jul; 152(7):1376-80. PubMed ID: 1627017 [TBL] [Abstract][Full Text] [Related]
23. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Harbison JW Stroke; 1992 Dec; 23(12):1723-7. PubMed ID: 1448821 [TBL] [Abstract][Full Text] [Related]
24. [Ticlopidine Aspirin Stroke Study]. Lima JM Arq Bras Cardiol; 1990 Mar; 54(3):240. PubMed ID: 2288515 [No Abstract] [Full Text] [Related]
25. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Gouya G; Arrich J; Wolzt M; Huber K; Verheugt FW; Gurbel PA; Pirker-Kees A; Siller-Matula JM Stroke; 2014 Feb; 45(2):492-503. PubMed ID: 24368560 [TBL] [Abstract][Full Text] [Related]
31. Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy. Habib GB Clin Cardiol; 2006 Jun; 29(6):244-8. PubMed ID: 16796073 [TBL] [Abstract][Full Text] [Related]
32. [Prevention and therapy of stroke]. Nervenarzt; 1994 May; 65(5 Suppl):1-8. PubMed ID: 9131086 [No Abstract] [Full Text] [Related]
33. Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Grotta JC; Norris JW; Kamm B Neurology; 1992 Jan; 42(1):111-5. PubMed ID: 1734290 [TBL] [Abstract][Full Text] [Related]
34. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Liao JK Circulation; 2007 Mar; 115(12):1615-21. PubMed ID: 17389280 [TBL] [Abstract][Full Text] [Related]
35. What have we learned from recent antiplatelet trials? Easton JD Neurology; 1998 Sep; 51(3 Suppl 3):S36-8. PubMed ID: 9744831 [TBL] [Abstract][Full Text] [Related]
37. Ticlopidine: a new platelet aggregation inhibitor. Ito MK; Smith AR; Lee ML Clin Pharm; 1992 Jul; 11(7):603-17. PubMed ID: 1617911 [TBL] [Abstract][Full Text] [Related]
38. Anticoagulants and antiplatelet agents in acute ischemic stroke. Pellegrino TR Va Med Q; 1998; 125(2):125-7. PubMed ID: 9577715 [No Abstract] [Full Text] [Related]
39. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Diener HC; Sacco R; Yusuf S; ; Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887 [TBL] [Abstract][Full Text] [Related]